Description:

RVMD is the ticker symbol for Revance Therapeutics, Inc., a biotechnology company listed on the New York Stock Exchange (NYSE). Revance Therapeutics specializes in the development and commercialization of innovative aesthetic and therapeutic treatments using its proprietary neuromodulator technology. The company is well-known for its DaxibotulinumtoxinA for Injection, commonly referred to as RT002, which has been approved by the FDA for the temporary improvement of the appearance of moderate to severe frown lines between the eyebrows (glabellar lines) in adults. Beyond aesthetics, Revance is also exploring applications of its technology in various therapeutic areas to address conditions such as overactive bladder and chronic migraine.

Data:

Yields: